Clinical Trial Detail

NCT ID NCT03543358
Title A Long-Term Study of Rovalpituzumab Tesirine
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications

cancer

Therapies

Rovalpituzumab Tesirine

Age Groups: adult senior

No variant requirements are available.